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Abstract
Pulmonary arterial hypertension (PAH) is usually a devastating condition with a poor prognosis.
Nearly 10 years ago, the underlying molecular basis of heritable PAH was elucidated with the
identification of mutations in the gene encoding the bone morphogenetic protein type II receptor
(BMPR-II). This discovery is now beginning to suggest novel approaches to therapy in heritable PAH.
Moreover, recent studies provide evidence that dysfunction of the BMPR-II pathway is a feature of
non-familial forms of PAH, broadening the scope for intervention in this pathway.
Introduction and context
Idiopathic and familial forms of pulmonary arterial
hypertension (PAH) continue to carry a poor prognosis
despite significant improvementsinthe treatment ofthese
and related conditions over the past 15 years. Existing
therapies are based on the replacement of prostanoids,
inhibition of the endothelin pathway, or enhancement
of nitric oxide signaling. Although these therapies have
improved symptoms and possibly survival of some
patients, additional approaches founded on a more
thorough understanding of the cell and molecular
pathobiology of PAH are required. Nearly 10 years ago,
heterozygous germline mutations in the gene encoding
bone morphogenetic protein type II receptor (BMPR-II),
on chromosome 2q33, were identified in families affected
by PAH [1,2]. To date, mutations in BMPR-II have been
identified in nearly 80% of affected families. In addition,
10-40% of apparently sporadic cases of idiopathic PAH
have been found to harbour mutations in BMPR-II [3].
Mutations have been identified in almost all of the coding
exons of the BMPR2 gene. Approximately 30% of
mutations are missense, causing substitution of highly
conserved amino acids in important functional domains
of the receptor (e.g., the ligand-binding or kinase
domains) [3]. The remaining (approximately 70%)
comprise nonsense, frameshift, and splice-site defects,
and gene rearrangements. These predict premature termi-
nation of the transcript with likely loss through the
process of nonsense-mediated decay (NMD). Disease
penetrance in mutation carriers varies between families
but is usually less than 50%. This important observation
suggests that, although heterozygous mutation in BMPR-II
increases the risk for PAH more than 10
5-fold, some
additional environmental or genetic factor seems to be a
requirement for disease manifestation [4]. Evidence for
genotype-phenotype correlations is slowly emerging in
that missense mutations have been associated with earlier
age of onset and increased penetrance compared with
other mutations [5]. In addition, certain low-penetrance
alleles seem more likely to occur in idiopathic PAH or
disease associated with other known triggers [3,6].
BMPR-II is a type II receptor member of the transforming
growth factor-beta (TGF-b) superfamily. As with other
TGF-b family members, BMPs signal via complexes
comprising heterodimers of type I and type II receptors
[7]. The type II receptor is a constitutively active serine-
threonine kinase, which in the presence of ligand
phosphorylates the type I receptor. The type I receptor
then phosphorylates a family of proteins termed Smads,
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transcription or in the presence of DNA-binding
partners. BMPs typically activate Smads 1, 5, and 8,
whereas the TGF-b receptors typically activate Smads 2
and 3. Smad 4 is a common partner Smad that lacks a
DNA-binding domain but is necessary for entry of the
receptor-activated Smads to the nucleus.
In lung tissue from patients with heritable PAH, BMPR-II
protein expression and phospho-Smad1 expression are
reduced [8,9]. Of note, expression of these key parts of
the BMP signaling pathway is also reduced in PAH
patients who have no identifiable mutation in BMPR-II
[8]. In pulmonary artery smooth muscle cells (PASMCs)
isolated from patients with BMPR-II mutations, phos-
pho-Smad1/5 activation in response to BMPs is sup-
pressed, as is the activation of key BMP target genes,
including the inhibitors of differentiation (Id) genes
[10]. The BMP/BMPR-II/Smad1/Id gene axis appears to
be growth-suppressive in PASMCs and pro-apoptotic
[9,11]. Overexpression of mutant BMPR-II in vascular
smooth muscle cells of transgenic mice appears sufficient
to induce the development of pulmonary hypertension
in these animals [12], whereas heterozygous BMPR2-null
mice have no clear phenotype [13,14]. These findings
likely indicate the need for a critical reduction in the
BMPR-II activity below a threshold for the manifestation
of disease. It is possible that additional triggers necessary
for disease manifestation may further disrupt expression
of key components of this pathway or indeed BMPR-II
itself. Immunohistochemistry and in vitro studies suggest
that BMPR-II is most highly expressed on the vascular
endothelium. In contrast to PASMCs, BMPs via BMPR-II/
Smad1/5 and Id1 are thought to enhance proliferation
and reduce apoptosis of endothelial cells [15]. Condi-
tional knockout of endothelial BMPR-II is sufficient
to cause pulmonary hypertension in a proportion of
mice [16].
Major recent advances
In terms of the translational value of the molecular
findings, two major questions arise. First, can the
restoration of BMPR-II function or expression prevent,
or preferably reverse, the development of pulmonary
hypertension? Second, what are the consequences to
the cell of reduced BMPR-II expression or function and
can these be targeted? We now know that reduced
BMPR-II expression is a key feature of the two most
commonly used rat models of PAH: chronic hypoxia
[17,18] and exposure to the plant alkaloid, monocrota-
line [17,19]. Prevention of the reduction of BMPR-II
expression by adenovirally transduced lung endothelial
targeting of BMPR-II ameliorates the development
of pulmonary hypertension in chronically hypoxic
rats [20]. The same targeted approach is successful in
the monocrotaline model, although transduction via
the airways failed to have an effect [21]. There are
additional approaches that might be used to restore
BMPR-II function. For example, many of the mutations
result in NMD of the transcript. Agents that improve
translational read-through of the transcript would
therefore be useful for mutations in which the resulting
protein would retain some function [22]. Many of the
missense mutations occur in the ligand-binding
domain of BMPR-II and involve the substitution of
important cysteine residues that provide tertiary
structure to the molecule. These cysteine-substituted
mutants fail to traffic normally to the cell surface and
are held up within the endoplasmic reticulum. Though
mutated, these receptors retain kinase activity, can
associate with type I receptors, and retain some ligand-
binding capacity. It is possible to use chemical
chaperones to enhance mutant BMPR-II trafficking to
the cell surface and restore BMP signaling [23]. This
approach may be useful in this particular form of
mutation. In addition, it is possible that the endo-
plasmic reticulum stress response may be activated in
the presence of these mutations, which could also be a
target for intervention.
One example of a pathway that is altered as a
consequence of reduced BMP signaling is the TGF-b
pathway via the TGF-b type 1 receptor, activin receptor-
like kinase 5 (ALK-5). Several studies have now
confirmed that ALK-5 inhibition can prevent or reverse
established pulmonary hypertension in rodent models
[17,24,25]. Another consequence of reduced BMPR-II
function appears to be the increased expression of pro-
inflammatory cytokines and inflammation [26]. These
findings are still emerging but again provide additional
targets for intervention.
Future directions
Further advances are required to develop a robust mouse
model of BMPR-II mutation that consistently leads to
pulmonary hypertension and vascular remodeling. This
will depend on the identification of a trigger or second hit
that precipitates disease. The unique conditions faced by
the lung circulation and the localization of disease to that
vascular bed are likely clues to solving this enigma. Such
models will allow the testing in vivo of novel therapies
designed to target BMPR-II or the BMP signaling pathway.
A further challenge is to more fully understand the
consequences to the vascular cell of BMPR-II mutation.
Evidence is emerging that non-canonical signaling or
additional hitherto unknown functions of BMPR-II may
provide further insight into pathobiology and ultimately
therapy.
Page 2 of 3
(page number not for citation purposes)
f1000 Biology Reports 2010, 2:22 http://f1000.com/reports/biology/content/2/22Abbreviations
ALK-5, activin receptor-like kinase 5; BMP, bone
morphogenetic protein; BMPR-II, bone morphogenetic
protein type II receptor; Id, inhibitors of differentiation;
NMD, nonsense-mediated decay; PAH, pulmonary
arterial hypertension; PASMC, pulmonary artery smooth
muscle cell; TGF-b, transforming growth factor-beta.
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